Skip to main content
. 2017 May 11;51(1):104–114. doi: 10.3892/ijo.2017.3996

Table IV.

Immunoreactivity of T47D cells treated with CM from M1 or M2 macrophages.

Treatment ERα ERβ1 PR Ki-67 uPAR
RPMI 5% FCS +++ +++ +++ +++
M1 CM + +++ ++ +
M2 CM + +++ +++ ++

ERα, estrogen receptor α; ERβ1, estrogen receptor β1; PR, progesterone receptor; uPAR, urokinase-type plasminogen activator receptor. +++, very strong immunoreactivity; ++, strong immunoreactivity; +, weak immunoreactivity; −, negative immunoreactivity.